Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial

This prospective, multicenter, community‐based and academic‐based, open‐label, investigator‐initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG‐IFN) alfa‐2b plus a flat or weight‐based dose of ribavirin (RBV) in adults with chronic hepatitis C. Patients (n = 5027) were r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2007-10, Vol.46 (4), p.971-981
Hauptverfasser: Jacobson, Ira M., Brown, Robert S., Freilich, Bradley, Afdhal, Nezam, Kwo, Paul Y., Santoro, John, Becker, Scott, Wakil, Adil E., Pound, David, Godofsky, Eliot, Strauss, Robert, Bernstein, David, Flamm, Steven, Pauly, Mary Pat, Mukhopadhyay, Pabak, Griffel, Louis H., Brass, Clifford A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This prospective, multicenter, community‐based and academic‐based, open‐label, investigator‐initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG‐IFN) alfa‐2b plus a flat or weight‐based dose of ribavirin (RBV) in adults with chronic hepatitis C. Patients (n = 5027) were randomly assigned to receive PEG‐IFN alfa‐2b 1.5 μg/kg/week plus flat‐dose (800 mg/day) or weight‐based (800‐1400 mg/day) RBV for 48 weeks (patients with genotype 1, 4, 5, or 6) and for 24 or 48 weeks (genotype 2/3 patients). Primary end point was sustained virologic response (undetectable [
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.21932